Patents by Inventor Gabriela Garcia
Gabriela Garcia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11318527Abstract: A method of manufacturing for finishing ceramic core flash. Locating a first hole on a ceramic core by a laser sensor on a robot. Probing for a center of the first hole by a force-torque sensor on the robot. Scanning for an axial position of a second hole on the ceramic core. Scanning for a third hole on the ceramic core. Probing for a center of the third hole. Determining axial and radial scale factors based on the first hole location and the third hole location. Uploading the axial and radial scale factors to the robot Multiplying the X component position by the axial scale factor and the Z component position by the radial scale factor in an array format. Cutting a designated scaled location along the ceramic core to remove flash. Repeating process for additional scaled locations along the ceramic core.Type: GrantFiled: June 19, 2018Date of Patent: May 3, 2022Assignee: SIEMENS ENERGY GLOBAL GMBH & CO. KGInventors: Timothy Troyer, Gabriela Garcia-Antunez, Robert Bruce, Andrew Belling, Lara Richerson, Douglas Bibb
-
Patent number: 11173180Abstract: The present application is directed to compositions and methods for treating a subject with cancer and/or increasing migration of a mesenchymal stromal cells (MSCs) stimulated with a recombinant autocrine motility factor (rAMF) to a tumor or a tumor cell, e.g. hepatocellular carcinoma (HCC). In addition, methods for increasing adhesion of MSCs to endothelial cells with rAMF are disclosed. In some embodiments, the MSCs comprise a therapeutic agent, e.g., an anti-tumor agent.Type: GrantFiled: February 9, 2018Date of Patent: November 16, 2021Assignee: Consejo National de Investigaciones Cientificas y Tecnicas (CONICET)Inventors: Guillermo Daniel Mazzolini, Mariana Gabriela Garcia, Juan Bayo
-
Publication number: 20210237146Abstract: A method of manufacturing for finishing ceramic core flash. Locating a first hole on a ceramic core by a laser sensor on a robot. Probing for a center of the first hole by a force-torque sensor on the robot. Scanning for an axial position of a second hole on the ceramic core. Scanning for a third hole on the ceramic core. Probing for a center of the third hole. Determining axial and radial scale factors based on the first hole location and the third hole location. Uploading the axial and radial scale factors to the robot Multiplying the X component position by the axial scale factor and the Z component position by the radial scale factor in an array format. Cutting a designated scaled location along the ceramic core to remove flash. Repeating process for additional scaled locations along the ceramic core.Type: ApplicationFiled: June 19, 2018Publication date: August 5, 2021Inventors: Timothy Troyer, Gabriela Garcia-Antunez, Robert Bruce, Andrew Belling, Lara Richerson, Douglas Bibb
-
Publication number: 20190119401Abstract: Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.Type: ApplicationFiled: May 31, 2018Publication date: April 25, 2019Inventors: Victor MOYO, Gabriela GARCIA
-
Publication number: 20190022143Abstract: The present application is directed to compositions and methods for treating a subject with cancer and/or increasing migration of a mesenchymal stromal cells (MSCs) stimulated with a recombinant autocrine motility factor (rAMF) to a tumor or a tumor cell, e.g. hepatocellular carcinoma (HCC). In addition, methods for increasing adhesion of MSCs to endothelial cells with rAMF are disclosed. In some embodiments, the MSCs comprise a therapeutic agent, e.g., an anti-tumor agent.Type: ApplicationFiled: February 9, 2018Publication date: January 24, 2019Inventors: Guillermo Daniel MAZZOLINI, Mariana Gabriela GARCIA, Juan BAYO
-
Patent number: 10043364Abstract: Provided is a security device, comprising: a sensor that senses a presence in a vehicle and generates a presence signal; an ignition state detection device that detects a state of the vehicle, and generates a status signal; and a rules processor that determines from the presence signal and the status signal whether an alarm or message is to be generated.Type: GrantFiled: March 13, 2017Date of Patent: August 7, 2018Assignee: WALMART APOLLO, LLCInventor: Juana Gabriela Garcia
-
Publication number: 20170291957Abstract: Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.Type: ApplicationFiled: November 8, 2016Publication date: October 12, 2017Inventors: Victor MOYO, Gabriela GARCIA
-
Publication number: 20170263098Abstract: Provided is a security device, comprising: a sensor that senses a presence in a vehicle and generates a presence signal; an ignition state detection device that detects a state of the vehicle, and generates a status signal; and a rules processor that determines from the presence signal and the status signal whether an alarm or message is to be generated.Type: ApplicationFiled: March 13, 2017Publication date: September 14, 2017Inventor: Juana Gabriela Garcia
-
Patent number: 9518130Abstract: Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.Type: GrantFiled: October 20, 2014Date of Patent: December 13, 2016Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Victor Moyo, Gabriela Garcia
-
Publication number: 20160220612Abstract: The present application is directed to compositions and methods for treating a subject with cancer and/or increasing migration of a mesenchymal stromal cells (MSCs) stimulated with a recombinant autocrine motility factor (rAMF) to a tumor or a tumor cell, e.g. hepatocellular carcinoma (HCC). In addition, methods for increasing adhesion of MSCs to endothelial cells with rAMF are disclosed. In some embodiments, the MSCs comprise a therapeutic agent, e.g., an anti-tumor agent.Type: ApplicationFiled: September 5, 2014Publication date: August 4, 2016Inventors: Guillermo Daniel MAZZOLINI, Mariana Gabriela GARCIA, Juan BAYO
-
Publication number: 20150231238Abstract: Provided are methods for overcoming resistance to an ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor. The resistance may be acquired resistance to an EGFR inhibitor, such as acquired resistance to gefitinib. In the methods provided, a subject exhibiting resistance to an ErbB pathway inhibitor is selected and both an ErbB 3 inhibitor and a second ErbB pathway inhibitor are administered to the subject, such as an EGFR inhibitor or a HER2 inhibitor. Also provided are methods for inhibiting the growth of a tumor comprising a T790M EGFR mutation by contacting the tumor with an ErbB3 inhibitor and an EGFR inhibitor. Compositions for overcoming resistance to an ErbB pathway inhibitor, comprising both an ErbB 3 inhibitor and a second ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor, are also provided.Type: ApplicationFiled: March 15, 2012Publication date: August 20, 2015Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Gabriela Garcia, William Kubasek, Maria Johanna Lahdenranta, Gavin MacBeath, Charlotte McDonagh, Victor Moyo, Matthew David Onsum, Birgit Schoeberl, Mark Sevecka, Marisa Wainszelbaum, Bo Zhang
-
Publication number: 20150132292Abstract: Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.Type: ApplicationFiled: October 20, 2014Publication date: May 14, 2015Inventors: Victor MOYO, Gabriela GARCIA
-
Patent number: 8895001Abstract: Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.Type: GrantFiled: March 11, 2011Date of Patent: November 25, 2014Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Victor Moyo, Gabriela Garcia
-
Publication number: 20140134170Abstract: Provided are methods of suppressing growth of hormone refractory breast tumors by contacting tumor cells with an ErbB3 inhibitor, preferably an anti-ErbB3 antibody. Also provided are methods for treating hormone refractory breast cancer in a patient by administering to the patient an inhibitor of heregulin binding to ErbB3 or to ErbB2/ErbB3 heterodimer, which inhibitor is an anti-ErbB3 antibody or an anti-ErbB2 antibody. The treatment methods can further comprise selecting a patient having a hormone refractory breast cancer and then administering the inhibitor to the patient. The treatment methods may also comprise administering an estrogen receptor antagonist, or an aromatase inhibitor to the patent and may at further comprise administering to the patient at least one additional anti-cancer agent that is not an ErbB3 inhibitor, an estrogen receptor antagonist, or an aromatase inhibitor to the patient in combination with the ErbB3 inhibitor.Type: ApplicationFiled: March 12, 2012Publication date: May 15, 2014Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Gabriela Garcia, William Kubasek, Gavin Macbeath, Victor Moyo
-
Patent number: 8697628Abstract: The present invention provides compounds and compositions that modulate adenosine monophosphate deaminase (AMPD) and methods for using the same to treat a clinical condition associated with the metabolic syndrome or a disease associated with the metabolic syndrome. In particular, the present invention provides a compound and a composition comprising a selective AMPD2 inhibitor and methods for using the same, for example, to treat a clinical condition associated with metabolic syndrome as well as diseases manifested by the metabolic syndrome.Type: GrantFiled: January 13, 2011Date of Patent: April 15, 2014Assignee: The Regents of the University of Colorado, a body corporateInventors: Gabriela Garcia, Richard J. Johnson, Christopher J. Rivard, Miguel A. Lanaspa-Garcia
-
Publication number: 20130209484Abstract: The present invention provides compounds and compositions that modulate adenosine monophosphate deaminase (AMPD) and methods for using the same to treat a clinical condition associated with the metabolic syndrome or a disease associated with the metabolic syndrome. In particular, the present invention provides a compound and a composition comprising a selective AMPD2 inhibitor and methods for using the same, for example, to treat a clinical condition associated with metabolic syndrome as well as diseases manifested by the metabolic syndrome.Type: ApplicationFiled: January 13, 2011Publication date: August 15, 2013Inventors: Gabriela Garcia, Richard J. Johnson, Christopher J. Rivard, Miguel A. Lanaspa-Garcia
-
Publication number: 20130034548Abstract: Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.Type: ApplicationFiled: March 11, 2011Publication date: February 7, 2013Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Victor Moyo, Gabriela Garcia